Research progress in drugs for chronic obstructive pulmonary disease therapy

LUO Zhicheng; WU Guozhen; YUAN Xing

doi:10.3969/j.issn.1006-0111.2017.03.003

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Volume 35 Issue 3

Turn off MathJax

Article Contents

Article Navigation > Journal of Pharmaceutical Practice and Service > 2017 > 35(3): 201-204,242

LUO Zhicheng, WU Guozhen, YUAN Xing. Research progress in drugs for chronic obstructive pulmonary disease therapy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 201-204,242. doi: 10.3969/j.issn.1006-0111.2017.03.003

Citation:

LUO Zhicheng, WU Guozhen, YUAN Xing. Research progress in drugs for chronic obstructive pulmonary disease therapy[J]. Journal of Pharmaceutical Practice and Service, 2017, 35(3): 201-204,242. doi: 10.3969/j.issn.1006-0111.2017.03.003

Research progress in drugs for chronic obstructive pulmonary disease therapy

doi: 10.3969/j.issn.1006-0111.2017.03.003

1.
School of Pharmacy, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China
2.
School of Pharmacy, Second Military Medical University, Shanghai 200433, China

Received Date: 2016-09-27
Rev Recd Date: 2017-02-23

Abstract

Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease characterized by incompletely reversible airflow limitation and progressive course. The pathogenesis of COPD is complicated. Clinical symptoms include declining pulmonary function, airway and lung inflammation, cough, emaciation, low activity and so on. In the past, the medications for COPD treatment were mainly bronchodilators and anti-inflammatory drugs.With the better understanding of its pathogenesis, anti-oxidative drugs have also been used in the clinical treatment of COPD recently. This article reviews the development of drugs which include bronchodilators, anti-inflammatory drugs and anti-oxidative drugs for the therapy of COPD.
- COPD,
- drugs for therapy,
- bronchiectasis,
- anti-inflammatory,
- anti-oxidant

References

[1]	中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013年修订版)(二)[J]. 全科医学临床与教育, 2013, 36(6): 484-491.
[2]	Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet, 2012, 380(9859): 2095-2128.
[3]	丁宁, 王胜. 慢性阻塞性肺疾病发病机制最新研究进展[J]. 临床肺科杂志, 2016, 21(1): 133-136.
[4]	徐庆庆, 李向阳. 抗胆碱能药物在慢性阻塞性肺疾病中的临床应用[J]. 中国医药指南, 2015, 13(29): 37-39.
[5]	任艳平, 石蕊, 张睿,等. 噻托溴铵治疗慢性阻塞性肺疾病有效性和安全性的Meta分析[J]. 中国药房, 2015, 26(21): 2947-2949.
[6]	夏玲红, 孙黎, 金冠钦,等. 治疗慢性阻塞性肺病新药阿地溴铵[J]. 中国新药杂志, 2013, 22(5): 499-501.
[7]	Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the anttainstudy[J]. Eur Respir J, 2012, 40(4): 830-836.
[8]	Kerwin E, Hébert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the glow2 study[J]. Eur Respir J, 2012, 40(5): 1106-1114.
[9]	Kew K. Long-acting beta2-agonists for chronic obstructive pulmonary disease[J]. Cochrane Database Syst Rev, 2006, 3(3): 117-118.
[10]	Kornmann O, Dahl R, Centanni S, et al. Once daily indacaterol versus twice daily salmeterol for COPD: a placebo controlled comparison[J]. Euro Respir J, 2011, 37(2): 273-279.
[11]	李媛, 林青. 茶碱类药物的研究进展及应用[J]. 中国医药指南, 2013, 11(4): 421-422.
[12]	Iiboshi H, Ashitani J, Katoh S. Long-term treatment with theophylline reduces neutrophils, interleukin-8 and tumor necrosis factor-α in the sputum of patients with chronic obstructive pulmonary disease[J]. Pulm Pharmacol Ther, 2007, 20(1): 46-51.
[13]	Barnes PJ. Theophylline: new perspectives for an old drug[J]. Am J Respir Crit Care Med, 2003, 167(6): 813-818.
[14]	赵新云, 孔辉, 解卫平. 炎症反应与慢性阻塞性肺疾病肺功能分级[J]. 国际呼吸杂志, 2013, 33(17): 1343-1346.
[15]	钟佰强, 钱丽芬, 黄宝贤,等. 不同剂量糖皮质激素对慢性阻塞性肺疾病患者急性加重期炎性介质的影响及临床意义[J]. 中华老年医学杂志, 2014, 33(4): 376-379.
[16]	Battaglia S, Cardillo I, Lavorini F, et al. Safety considerations of inhaled corticosteroids in the elderly[J]. Drugs Aging, 2014, 31(11): 787-796.
[17]	赵焕, 石寒冰, 毕红霞. 布地奈德联合福莫特罗雾化吸入治疗慢性阻塞性肺疾病的临床疗效观察[J]. 中国全科医学, 2013, 15(35): 4219-4221.
[18]	Yan JH, Gu WJ, Pan L. Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis[J].Pulm Pharmacol Ther, 2014, 27(1): 83-89.
[19]	宋毅, 徐莉琼, 李婵,等. 孟鲁司特治疗慢性阻塞性肺病65例疗效观察[J]. 四川医学, 2012, 33(3): 436-438.
[20]	李强, 邹小新, 饶常红. 孟鲁司特联合噻托溴铵治疗慢性阻塞性肺疾病疗效的研究[J]. 重庆医学, 2013, 42(19): 2278-2280.
[21]	Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD[J]. N Engl J Med, 2011, 365(8): 689-698.
[22]	Neukamm A, HΦiseth AD, Einvik G, et al. Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial[J].J Intern Med, 2014, 278(1): 59-67.
[23]	王翠茹, 李玲, 韩云霞,等. 慢性阻塞性肺疾病发病机制的研究进展[J]. 当代医学, 2011, 17(32): 19-20.
[24]	Santus P, Corsico A, Solidoro P, et al. Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteine[J]. COPD, 2014, 11(6): 705-717.
[25]	Tse HN, Raiteri L, Wong KY, et al. High-dose N-acetylcysteine in stable chronic obstructive pulmonary disease: the 1 year, double-blind, randomized, placebo-controlled HIACE study[J]. Chest, 2013, 144(1): 106-118.
[26]	张瑞. 盐酸氨溴索雾化对COPD患者氧化应激的影响[J]. 临床肺科杂志, 2013, 18(5): 894-895.
[27]	Esposito A, Valentino MR, Bruzzese D, et al. Effect of carbocisteine in prevention of exacerbation of chronic obstructive pulmonary disease (CAPRI study): an observational study[J].Pulm Pharmacol Ther, 2016, 37(1): 85-88.
[28]	Sussan TE, Rangasamy T, Blake DJ, et al. Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice[J].Proc Natl Acad Sci USA, 2009, 106(1): 250-255.
[29]	Yu W, Fu YC, Wang W. Cellular and molecular effects of resveratrol in health and disease[J].J Cell Biochem, 2012, 113(3): 752-759.
[30]	He X, Wang L, Szklarz G, et al. Resveratrol inhibits paraquat-induced oxidative stress and fibrogenic response by activating the nuclear factor erythroid 2-related factor 2 pathway[J].J Pharmacol Exp Ther, 2012, 342(1): 81-90.
[31]	Youn GS, Kwon DJ, Ju SM, et al. Curcumin ameliorates TNF-α-induced ICAM-1 expression and subsequent THP-1 adhesiveness via the induction of heme oxygenase-1 in the HaCaT cells[J].BMB Rep, 2013, 46(8): 410-415.

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Get Citation

PDF

XML

Article Metrics

Article views(2865) PDF downloads(1193) Cited by()

Proportional views

Research progress in drugs for chronic obstructive pulmonary disease therapy

1. School of Pharmacy, Jiangxi University of Traditional Chinese Medicine, Nanchang 330004, China

2. School of Pharmacy, Second Military Medical University, Shanghai 200433, China

Received Date: 2016-09-27

Rev Recd Date: 2017-02-23

Key words:

Abstract: Chronic obstructive pulmonary disease (COPD) is a chronic respiratory disease characterized by incompletely reversible airflow limitation and progressive course. The pathogenesis of COPD is complicated. Clinical symptoms include declining pulmonary function, airway and lung inflammation, cough, emaciation, low activity and so on. In the past, the medications for COPD treatment were mainly bronchodilators and anti-inflammatory drugs.With the better understanding of its pathogenesis, anti-oxidative drugs have also been used in the clinical treatment of COPD recently. This article reviews the development of drugs which include bronchodilators, anti-inflammatory drugs and anti-oxidative drugs for the therapy of COPD.

HTML

Reference (31)

[1]	中华医学会呼吸病学分会慢性阻塞性肺疾病学组. 慢性阻塞性肺疾病诊治指南(2013年修订版)(二)[J]. 全科医学临床与教育, 2013, 36(6): 484-491.
[2]	Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010[J]. Lancet, 2012, 380(9859): 2095-2128.
[3]	丁宁, 王胜. 慢性阻塞性肺疾病发病机制最新研究进展[J]. 临床肺科杂志, 2016, 21(1): 133-136.
[4]	徐庆庆, 李向阳. 抗胆碱能药物在慢性阻塞性肺疾病中的临床应用[J]. 中国医药指南, 2015, 13(29): 37-39.
[5]	任艳平, 石蕊, 张睿,等. 噻托溴铵治疗慢性阻塞性肺疾病有效性和安全性的Meta分析[J]. 中国药房, 2015, 26(21): 2947-2949.
[6]	夏玲红, 孙黎, 金冠钦,等. 治疗慢性阻塞性肺病新药阿地溴铵[J]. 中国新药杂志, 2013, 22(5): 499-501.
[7]	Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the anttainstudy[J]. Eur Respir J, 2012, 40(4): 830-836.
[8]	Kerwin E, Hébert J, Gallagher N, et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with COPD: the glow2 study[J]. Eur Respir J, 2012, 40(5): 1106-1114.
[9]	Kew K. Long-acting beta2-agonists for chronic obstructive pulmonary disease[J]. Cochrane Database Syst Rev, 2006, 3(3): 117-118.
[10]	Kornmann O, Dahl R, Centanni S, et al. Once daily indacaterol versus twice daily salmeterol for COPD: a placebo controlled comparison[J]. Euro Respir J, 2011, 37(2): 273-279.
[11]	李媛, 林青. 茶碱类药物的研究进展及应用[J]. 中国医药指南, 2013, 11(4): 421-422.
[12]	Iiboshi H, Ashitani J, Katoh S. Long-term treatment with theophylline reduces neutrophils, interleukin-8 and tumor necrosis factor-α in the sputum of patients with chronic obstructive pulmonary disease[J]. Pulm Pharmacol Ther, 2007, 20(1): 46-51.
[13]	Barnes PJ. Theophylline: new perspectives for an old drug[J]. Am J Respir Crit Care Med, 2003, 167(6): 813-818.
[14]	赵新云, 孔辉, 解卫平. 炎症反应与慢性阻塞性肺疾病肺功能分级[J]. 国际呼吸杂志, 2013, 33(17): 1343-1346.
[15]	钟佰强, 钱丽芬, 黄宝贤,等. 不同剂量糖皮质激素对慢性阻塞性肺疾病患者急性加重期炎性介质的影响及临床意义[J]. 中华老年医学杂志, 2014, 33(4): 376-379.
[16]	Battaglia S, Cardillo I, Lavorini F, et al. Safety considerations of inhaled corticosteroids in the elderly[J]. Drugs Aging, 2014, 31(11): 787-796.
[17]	赵焕, 石寒冰, 毕红霞. 布地奈德联合福莫特罗雾化吸入治疗慢性阻塞性肺疾病的临床疗效观察[J]. 中国全科医学, 2013, 15(35): 4219-4221.
[18]	Yan JH, Gu WJ, Pan L. Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis[J].Pulm Pharmacol Ther, 2014, 27(1): 83-89.
[19]	宋毅, 徐莉琼, 李婵,等. 孟鲁司特治疗慢性阻塞性肺病65例疗效观察[J]. 四川医学, 2012, 33(3): 436-438.
[20]	李强, 邹小新, 饶常红. 孟鲁司特联合噻托溴铵治疗慢性阻塞性肺疾病疗效的研究[J]. 重庆医学, 2013, 42(19): 2278-2280.
[21]	Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD[J]. N Engl J Med, 2011, 365(8): 689-698.
[22]	Neukamm A, HΦiseth AD, Einvik G, et al. Rosuvastatin treatment in stable chronic obstructive pulmonary disease (RODEO): a randomized controlled trial[J].J Intern Med, 2014, 278(1): 59-67.
[23]	王翠茹, 李玲, 韩云霞,等. 慢性阻塞性肺疾病发病机制的研究进展[J]. 当代医学, 2011, 17(32): 19-20.
[24]	Santus P, Corsico A, Solidoro P, et al. Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteine[J]. COPD, 2014, 11(6): 705-717.
[25]	Tse HN, Raiteri L, Wong KY, et al. High-dose N-acetylcysteine in stable chronic obstructive pulmonary disease: the 1 year, double-blind, randomized, placebo-controlled HIACE study[J]. Chest, 2013, 144(1): 106-118.
[26]	张瑞. 盐酸氨溴索雾化对COPD患者氧化应激的影响[J]. 临床肺科杂志, 2013, 18(5): 894-895.
[27]	Esposito A, Valentino MR, Bruzzese D, et al. Effect of carbocisteine in prevention of exacerbation of chronic obstructive pulmonary disease (CAPRI study): an observational study[J].Pulm Pharmacol Ther, 2016, 37(1): 85-88.
[28]	Sussan TE, Rangasamy T, Blake DJ, et al. Targeting Nrf2 with the triterpenoid CDDO-imidazolide attenuates cigarette smoke-induced emphysema and cardiac dysfunction in mice[J].Proc Natl Acad Sci USA, 2009, 106(1): 250-255.
[29]	Yu W, Fu YC, Wang W. Cellular and molecular effects of resveratrol in health and disease[J].J Cell Biochem, 2012, 113(3): 752-759.
[30]	He X, Wang L, Szklarz G, et al. Resveratrol inhibits paraquat-induced oxidative stress and fibrogenic response by activating the nuclear factor erythroid 2-related factor 2 pathway[J].J Pharmacol Exp Ther, 2012, 342(1): 81-90.
[31]	Youn GS, Kwon DJ, Ju SM, et al. Curcumin ameliorates TNF-α-induced ICAM-1 expression and subsequent THP-1 adhesiveness via the induction of heme oxygenase-1 in the HaCaT cells[J].BMB Rep, 2013, 46(8): 410-415.

Message Board

Research progress in drugs for chronic obstructive pulmonary disease therapy

doi: 10.3969/j.issn.1006-0111.2017.03.003

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views